| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA856: Upadacitinib for treating moderately to severely active ulcerative colitis |
|
Medicine details |
|
| Medicine name | upadacitinib (Rinvoq®) |
| Formulation | 15 mg,30 mg prolonged release tablets |
| Reference number | 4035 |
| Indication | Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. |
| Company | AbbVie Ltd |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/06/2022 |
| NICE guidance | TA856: Upadacitinib for treating moderately to severely active ulcerative colitis |